LLY vs QURE

Eli Lilly remains a pharmaceutical powerhouse with exceptional market leadership, especially driven by its GLP-1 agonist franchise (Mounjaro/Zepbound). The company possesses a robust R&D pipeline and substantial competitive advantages through intellectual property and scale. While LLY offers strong long-term growth and stability, its current market capitalization exceeding $1 trillion makes achiev...

uniQure's previous 10x potential, primarily tied to AMT-130 for Huntington's disease, has been severely hampered by recent developments. The FDA's criticism of the study design, requiring additional studies and delaying the BLA submission, coupled with multiple securities class-action lawsuits, represents a significant setback. While the long-term market opportunity for gene therapy in rare diseas...